Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (2172)	3/28/1999 3:31:00 PM
From: David Howe	Read Replies (2) \| Respond to of 10280

From Sepracor's web site. Not sure how up to date it is. Dave << Sepracor has recently completed the fall Phase III Seasonal Allergic Rhinitis (SAR) study as well as the Phase III Environmental Exposure Unit (ERM study of norastemizole and is awaiting trial results.) >> The link to the full report on Norastemizole. sepracor.com

To: Ed Ajootian who wrote (2172)	3/29/1999 1:42:00 PM
From: Bob Swift	Read Replies (1) \| Respond to of 10280

[Successful completion of the latest study on Norastemizole and filing the NDA] I forgot about this one which also is more potent and have no heart problem as the parental drug. This should be an easy one as FDA already requested a warning label on the parental drug, I think. I checked institutional holdings and found Fidelity been buying at a price as high as 129.5. Hope these funds start buying again at the current bargain basement price. After all they are supposedly long term investors. Looks like short term we have successfully tested 110 again which bounced back immediately three times in the past few months.